This was raised briefly in the webinar, but I wanted to talk a little bit about
this because I didn't quite get the reasoning when it was being presented.
To recap, there were 397 men in the ADT + Docetaxel arm and 393 men in the ADT only arm.
The therapy beyond progression was interesting because a large number of the ADT only arm never received any type of chemo. The breakdown is as follows:
393 ADT Only
- 129 had Docetaxel after progression
- 29 had Cabazitaxel after progression
- 23 had Mitoxantrone &or/Platinum after progression
216 of the ADT only arm never had any form of chemo at any time. That is over half the men in this trial.
On the other side (ADT + chemo): All 397 received chemo up front, but 114 of these that progressed, had additional forms of chemo. So, about 1/3 of these men had repeated chemo throughout the course of their disease.
We aren't sure why the 216 didn't have chemo. It could be a number of reasons. They could have been too ill to recieve it, didn't want it, quality of life issues, etc...
But doesn't it stand to reason that giving these 216 men chemo would have extended their lives? (Aren't there studies to show with chemo and without?)
And, doesn't this skew the numbers in favor of the ADT only arm?
Think about this...more than half didn't get any chemo, yet 1/3 of the ADT+chemo arm got the initial chemo + chemo later in their disease.
11/09 Dx at Age 44 ----------- 4.03
12/09 DaVinci Surgery,t3b,g9 <.05
2/10 Adj. Radiation ----------- <.05
3/11 PSA Rise/Scans/Spot ---- .09
on Pelvic Bone
4/11 HT/XGEVA/Spot Radiation -- .06
2012 -- <.015 (ADT3 until October)
2013 -- <.015 (off HT entire year)
6/2014 -- <.015 (20 months since last Lupron shot)